- Home
- Applications
- usa massachusetts
- clinic celiacshield trial
Show results for
Refine by
Clinic Celiacshield Trial Product Applications In Usa Massachusetts
18 applications found
Prancer RTSM provides the flexibility you need to explore all the possible paths for determining the optimal dose, patient population, and combination therapies within your Phase 2 ...
By4G Clinical based in Wellesley, MASSACHUSETTS (USA)
Our collective health depends on finding new vaccines and treatments for diseases and illnesses. Clinical trials are pivotal in getting medicines approved to help people in need. We invite you to learn about our clinical trial opportunities and how you may be able to make a ...
ByModerna, Inc. based in Cambridge, MASSACHUSETTS (USA)
People who have suffered a Traumatic Brain Injury have successfully used a REX. A clinical trial has been conducted by the Australian Institute of Neuro-rehabilitation (AIN), Nelson Bay, New South Wales (NSW), Australia and the University of Newcastle, NSW; and is supported by The Newcastle Permanent Charitable Foundation and Rex Bionics plc. The trial was open to volunteers from the Hunter Region of NSW, who have had a Stroke or Traumatic Brain Injury more than three months previously and have difficulty ...
ByRex Bionics Ltd based in Auckland, NEW ZEALAND
Now is the time to treat a larger population in your pivotal trials to support global submissions and market expansion. Prancer RTSM? helps you navigate the complexity of global supply chains as well as provides the complete data story needed for successful regulatory ...
By4G Clinical based in Wellesley, MASSACHUSETTS (USA)
REX is used by physiotherapists for people with mobility impairments, in rehabilitation centres in the US, the UK, the Middle East, Australia and New Zealand. ...
ByRex Bionics Ltd based in Auckland, NEW ZEALAND
Lysosomal diseases are a group of rare, genetic metabolic diseases in which cellular waste products build up in the body. These disorders are generally progressive and there is no cure. Many lysosomal diseases have no FDA-approved ...
ByEli Lilly and Company based in Indianapolis, INDIANA (USA)
Rare blood disorders are a group of rare genetic disorders where the blood does not clot properly. Existing therapies for blood disorders place a high burden on patients and caregivers, requiring infusions as often as multiple times each week over a patient’s ...
ByEli Lilly and Company based in Indianapolis, INDIANA (USA)
We are collaborating with leading hospitals, integrated health systems, medical centers and biobanks around the world to conduct studies in order to further develop and validate UDX's blood test for early cancer ...
ByUniversal Diagnostics SL based in Seville, SPAIN
With Qynapse we all benefit from earlier and more accurate monitoring of patients. Patients, practitioners, researchers and you – the payer, all benefit from earlier, more accurate central nervous system disease diagnosis and monitoring of patients throughout the care continuum. Qynapse has the potential to help lower costs, drive up quality outcomes and improve patient satisfaction. Are you ready to transform neuroscience with us? ...
ByQynapse based in Paris, FRANCE
Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of ...
ByFinch Therapeutics Group, Inc. based in Somerville, MASSACHUSETTS (USA)
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in a person’s mood, energy, and ability to function. Different from the normal ups and downs that everyone goes through, the symptoms of bipolar disorder are severe. They can result in damaged relationships, poor job or school performance, and even suicide. About 5.7 million American adults or about 2.6 percent of the population aged 18 and older in any given year, have bipolar ...
ByBrainsWay Ltd. based in Burlington, MASSACHUSETTS (USA)
See clearly and quickly with Qynapse’s AI-powered neuroimaging software platform. Our quest is to enhance your clinical trial design and increase the likelihood of trial success by leveraging our precise and objective AI-powered neuroimaging software platform. ...
ByQynapse based in Paris, FRANCE
GI Dynamics has taken all necessary COVID-19 precautions to ensure patient safety, which remains top priority. Patient screening for the STEP-1 pivotal trial of EndoBarrier has reopened at select sites and enrollment will be conducted according to site requirements and CDC/FDA ...
ByGI Dynamics, Inc. based in Boston, MASSACHUSETTS (USA)
From accelerating drug discovery to leveraging real world evidence, Centaur Labs provides life sciences innovators with high-quality medical data annotations at unprecedented speed and ...
ByCentaur Labs based in Boston, MASSACHUSETTS (USA)
Type 1 diabetes is a common chronic disease, affecting millions of people throughout the world, in which the immune system attacks the body’s own pancreatic cells, stopping the production of insulin. Though it was previously considered a childhood disease, type 1 diabetes is known to affect people at every age, and it has no ...
ByEli Lilly and Company based in Indianapolis, INDIANA (USA)
Seres’ microbiome therapeutics represent a transformative new approach to ...
BySeres Therapeutics, Inc. based in Cambridge, MASSACHUSETTS (USA)
Increase clinical translation with Organ-Chips for ADME-Tox assessments. Accurate ADME-Tox profiling of preclinical drug candidates remains a challenge. Preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies are pivotal to predicting human response. However, approximately 30% of drugs fail during human clinical trials due to adverse reactions despite promising preclinical study results, and another 60% fail due to lack of efficacy. As companies broaden the modality toolbox ...
ByEmulate based in Boston, MASSACHUSETTS (USA)
ViTrack is a platform technology with applications across the continuum of care. In 2015, with the support of MIT and Tufts, the founding team behind Dynocardia began their search for a fundamentally different approach to the measurement of blood pressure (BP) that can measure automatically, without the participation of the user, caregiver, or healthcare provider. After rigorous bench testing and ongoing clinical studies in the ICU, ViTrack technology is proven to offer accurate continuous, non-invasive blood ...
ByDynocardia, Inc. based in Cambridge, MASSACHUSETTS (USA)